180 related articles for article (PubMed ID: 16715034)
1. Effects of drotrecogin alfa activated on microcirculatory alterations in patients with severe sepsis.
De Backer D; Verdant C; Chierego M; Koch M; Gullo A; Vincent JL
Crit Care Med; 2006 Jul; 34(7):1918-24. PubMed ID: 16715034
[TBL] [Abstract][Full Text] [Related]
2. Microcirculatory alterations in patients with severe sepsis: impact of time of assessment and relationship with outcome.
De Backer D; Donadello K; Sakr Y; Ospina-Tascon G; Salgado D; Scolletta S; Vincent JL
Crit Care Med; 2013 Mar; 41(3):791-9. PubMed ID: 23318492
[TBL] [Abstract][Full Text] [Related]
3. Influence of drotrecogin alpha (activated) infusion on the variation of Bax/Bcl-2 and Bax/Bcl-xl ratios in circulating mononuclear cells: a cohort study in septic shock patients.
Bilbault P; Lavaux T; Launoy A; Gaub MP; Meyer N; Oudet P; Pottecher T; Jaeger A; Schneider F
Crit Care Med; 2007 Jan; 35(1):69-75. PubMed ID: 17133181
[TBL] [Abstract][Full Text] [Related]
4. Drotrecogin alfa (activated) for severe sepsis: could we consider a shorter treatment period in patients with a favorable course?
Ahishakiye D; Lorent S; De Backer D; Gottignies P; Vincent JL
J Crit Care; 2009 Dec; 24(4):590-4. PubMed ID: 19577419
[TBL] [Abstract][Full Text] [Related]
5. Effects of nitroglycerin on sublingual microcirculatory blood flow in patients with severe sepsis/septic shock after a strict resuscitation protocol: a double-blind randomized placebo controlled trial.
Boerma EC; Koopmans M; Konijn A; Kaiferova K; Bakker AJ; van Roon EN; Buter H; Bruins N; Egbers PH; Gerritsen RT; Koetsier PM; Kingma WP; Kuiper MA; Ince C
Crit Care Med; 2010 Jan; 38(1):93-100. PubMed ID: 19730258
[TBL] [Abstract][Full Text] [Related]
6. Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shock.
Dhainaut JF; Antonelli M; Wright P; Desachy A; Reignier J; Lavoue S; Charpentier J; Belger M; Cobas-Meyer M; Maier C; Mignini MA; Janes J
Intensive Care Med; 2009 Jul; 35(7):1187-95. PubMed ID: 19263034
[TBL] [Abstract][Full Text] [Related]
7. Predictors of hospital mortality for patients with severe sepsis treated with Drotrecogin alfa (activated).
Micek ST; Isakow W; Shannon W; Kollef MH
Pharmacotherapy; 2005 Jan; 25(1):26-34. PubMed ID: 15767217
[TBL] [Abstract][Full Text] [Related]
8. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.
Vincent JL; Angus DC; Artigas A; Kalil A; Basson BR; Jamal HH; Johnson G; Bernard GR;
Crit Care Med; 2003 Mar; 31(3):834-40. PubMed ID: 12626993
[TBL] [Abstract][Full Text] [Related]
9. Relationship between sublingual and intestinal microcirculatory perfusion in patients with abdominal sepsis.
Boerma EC; van der Voort PH; Spronk PE; Ince C
Crit Care Med; 2007 Apr; 35(4):1055-60. PubMed ID: 17334238
[TBL] [Abstract][Full Text] [Related]
10. Readministration of drotrecogin alfa (activated) in an adult with severe sepsis.
Scipione MR; Nogid B; Davanos E; DiGregorio RV
Am J Health Syst Pharm; 2011 Sep; 68(18):1711-5. PubMed ID: 21880886
[TBL] [Abstract][Full Text] [Related]
11. Results of severe sepsis treatment program using recombinant human activated protein C in Poland.
Kübler A; Mayzner-Zawadzka E; Durek G; Gaszyński W; Karpel E; Mikaszewska-Sokolewicz M; Majak P
Med Sci Monit; 2006 Mar; 12(3):CR107-12. PubMed ID: 16501420
[TBL] [Abstract][Full Text] [Related]
12. Microvascular response to red blood cell transfusion in patients with severe sepsis.
Sakr Y; Chierego M; Piagnerelli M; Verdant C; Dubois MJ; Koch M; Creteur J; Gullo A; Vincent JL; De Backer D
Crit Care Med; 2007 Jul; 35(7):1639-44. PubMed ID: 17522571
[TBL] [Abstract][Full Text] [Related]
13. Timing of drotrecogin alfa (activated) initiation in treatment of severe sepsis: a database cohort study of hospital mortality, length of stay, and costs.
Ernst FR; Johnston JA; Pulgar S; He J; Ball DE; Young JK; Cooper LM
Curr Med Res Opin; 2007 Jan; 23(1):235-44. PubMed ID: 17207305
[TBL] [Abstract][Full Text] [Related]
14. The use of drotrecogin alfa (activated) in solid organ transplant patients: a case series.
Berkman S; Weimert NA; Taber DJ; Baillie GM; Lin A; Baliga P; Chavin KD
Transpl Infect Dis; 2009 Jun; 11(3):269-76. PubMed ID: 19392728
[TBL] [Abstract][Full Text] [Related]
15. Alterations of adiponectin in the course of inflammation and severe sepsis.
Behnes M; Brueckmann M; Lang S; Putensen C; Saur J; Borggrefe M; Hoffmann U
Shock; 2012 Aug; 38(3):243-8. PubMed ID: 22744305
[TBL] [Abstract][Full Text] [Related]
16. Clinical response to unintentionally rapid infusion of drotrecogin alfa (activated).
Urban TM; Mitchell GA; Wellborn-Kim JJ; Terneus WF; Callahan CM; Mendes J; Webber SL
Am J Health Syst Pharm; 2010 Jul; 67(14):1174-7. PubMed ID: 20592322
[TBL] [Abstract][Full Text] [Related]
17. Drotrecogin alfa (activated) treatment of older patients with severe sepsis.
Ely EW; Angus DC; Williams MD; Bates B; Qualy R; Bernard GR
Clin Infect Dis; 2003 Jul; 37(2):187-95. PubMed ID: 12856210
[TBL] [Abstract][Full Text] [Related]
18. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.
Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; McL Booth FV
Surgery; 2006 Nov; 140(5):726-39. PubMed ID: 17084715
[TBL] [Abstract][Full Text] [Related]
19. 90-day follow-up of patients treated with Drotrecogin Alfa (activated) for severe sepsis: a Belgian open label study.
Decruyenaere J; De Backer D; Spapen H; Laterre PF; Raemaekers J; Rogiers P; Trine H; Sartral M; Haentjens T; Wagner T
Acta Clin Belg; 2009; 64(1):16-22. PubMed ID: 19317237
[TBL] [Abstract][Full Text] [Related]
20. [There is no effect of drotrecogin alfa in severe sepsis].
Gøtzsche PC
Ugeskr Laeger; 2013 Mar; 175(13):903. PubMed ID: 23734377
[No Abstract] [Full Text] [Related]
[Next] [New Search]
